CN101822684A - Compound combined preparation for preventing osteoarticular pain and preparation method thereof - Google Patents
Compound combined preparation for preventing osteoarticular pain and preparation method thereof Download PDFInfo
- Publication number
- CN101822684A CN101822684A CN 201010184471 CN201010184471A CN101822684A CN 101822684 A CN101822684 A CN 101822684A CN 201010184471 CN201010184471 CN 201010184471 CN 201010184471 A CN201010184471 A CN 201010184471A CN 101822684 A CN101822684 A CN 101822684A
- Authority
- CN
- China
- Prior art keywords
- agent
- glucosamine
- parts
- preparation
- lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a compound combined preparation for preventing osteoarticular pain and a preparation method thereof; the preparation comprises an active component glucosamine or combinations of more than one or two of the glucosamine and other active components chondroitin sulfate, dimethyl sulfoxide and collagen protein, and the glucosamine is glucosamine sulfate, hydrochloride, phosphate or the mixture thereof; and auxiliary materials comprise excipient, disintegration agent, lubricant, adhesive, stabilizer and wetting agent. The invention has good curing and preventing functions to injury in arthritis and joint movement, the prepared tablets have the advantages of good disintegration performance, high dissolution speed and quick effect, the used amount of the raw materials and all the auxiliary materials reaches the best ratio, the product stability is improved, and the absorption utilization rate is high.
Description
Technical field
The invention belongs to glucosamine Medicines and Health Product technical field, be specifically related to a kind of compound combined formulation of preventing and treating osteoarthrosis pain and preparation method thereof that is used to.
Background technology
Osteoarthritis is common a kind of chronic arthritis, and people are always at the medicine of seeking and explore the osteoarthritis PD for many years.For a long time, people use aspirin always, and non-steroidal analgesic etc. is helped the patient and palliated the agonizing sufferings.These medicine life-time service, the effect that has reduces gradually, the generation flatulence that has, side effect such as stomachache.Arthritis mainly is the degeneration and the Secondary cases hyperosteogeny of articular cartilage.Because the mucosa of junction, joint is formed by containing sulfoprotein and glucamine etc.The Protocollagen of sulfur-bearing and glucamine etc. have the generation that promotes collagen protein, increase the combination of water, help to repair the function of damage cartilage.Can make injured cartilage recover normal, periosteum liquid is denseer, toughness more, thus strengthen the defencive function of periosteum, alleviate osteoarticular friction, reduce painful.
Glucosamine is a kind of natural amino monosaccharide, is the most important monosaccharide of poly-glucosamine and proteoglycan in the formation articular cartilage substrate.Glucosamine can be blocked the pathological process of osteoarthritis, and the progress that wards off disease is improved joint motion, alleviating pain, and do not have significant side effects.But owing to adjunct ingredient, there are problems such as product efficacy is single, absorption rate is low in the existing glucosamine class health food.In addition, the most difficult work is the particulate preparation of D-glucosamine and determines specific adjuvant combination and ratio that the major part that can implement is in theory write out a prescription, and does not all reach the prescription of tablet in the reality screening.The consumption of raw material and the improper ratio of various adjuvants makes and draws moist increase greatly, has reduced the stability of product.
Summary of the invention
The purpose of this invention is to provide a kind of compound combined formulation of preventing and treating osteoarthrosis pain and preparation method thereof that is used to, it has solved problems such as product efficacy is single in the existing glucosamine class health food, absorption rate is low, creatively screen and determine to have the preparation of specific composition, the stability of product is strengthened, meet people's medication requirement more.
Technical solution of the present invention is to comprise active component and adjuvant, described active component is one or more the combination in glucosamine or glucosamine and other active component chondroitin sulfate, dimethyl sulfone, the collagen protein, and glucosamine is glucosamine sulphate or hydrochlorate or phosphate or its mixture; Adjuvant comprises excipient, disintegrating agent, lubricant, binding agent, stabilizing agent, wetting agent, described excipient is a starch, microcrystalline Cellulose, sucrose, lactose, dextrin, mannitol, the combination of one or more in the calcium phosphate, disintegrating agent is a crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium, the combination of one or more in the cross-linking sodium carboxymethyl cellulose, lubricant is a magnesium stearate, stearic acid, the combination of one or both in the micropowder silica gel, binding agent is a polyvinylpyrrolidone, sodium carboxymethyl cellulose, starch, the combination of one or more in the hydroxypropyl emthylcellulose, stabilizing agent is a tartaric acid, and wetting agent is water or methanol or ethanol.
The weight proportion of each component of the present invention is as follows: 200～800 parts of glucosamine, 200～500 parts of chondroitin sulfate, 100～400 parts of collagen protein, 100～300 parts of dimethyl sulfones, 1～200 part of excipient, 1～40 part of binding agent, 1～100 part of disintegrating agent, 1～50 part of lubricant, 0.1～1 part of stabilizing agent, wetting agent is an amount of.
Adjuvant of the present invention can also comprise the coating pre-mixing agent, and the component of described coating pre-mixing agent solution is one or more the mixing in titanium dioxide, polyoxyethylene, Pulvis Talci, Polyethylene Glycol, hydroxypropyl emthylcellulose, the lecithin.
The weight proportion of each component of the present invention can also be as follows: 200～800 parts of glucosamine, 200～500 parts of chondroitin sulfate, 100～400 parts of collagen protein, 100～300 parts of dimethyl sulfones, 1～200 part of excipient, 1～40 part of binding agent, 1～100 part of disintegrating agent, 1～50 part of lubricant, 0.1～1 part of stabilizing agent, 1～100 part of coating pre-mixing agent, wetting agent is an amount of.
The compound combined formulation that the present invention is used to prevent and treat osteoarthrosis pain is to carry out according to the following steps:
1) part binding agent and stabilizing agent are mixed, being configured to concentration with the mixed solvent of an amount of methanol and water is 1～25% binder solution, fully is dissolved to clear;
2) glucosamine is pulverized, crossed 60～120 mesh sieves;
3) stirred mixing 1～10 minute in the binding agent dry powder input wet granulator with glucosamine and remainder;
4) add an amount of methanol and stirred 1～3 minute, left standstill 1～10 minute;
5) evenly, slowly add the solution of the binding agent of step 1 configuration, liquid feeding is granulated while stirring, behind the corning, and strict control inlet temperature, drying is crossed 12～20 mesh sieves;
6) other active component of adding and excipient, disintegrating agent, lubricant fully mix in step 5 gained granule, tabletting behind the mensuration intermediate content;
7) preparation coating pre-mixing agent solution, compound concentration is 1～18%, inlet temperature, sheet bed tempertaure, leaving air temp during the control coating carry out coating to the tablet of step 6 gained.
The present invention as active component, has good curing and a preventive effect to arthritis, joint motions are impaired by glucosamine, chondroitin sulfate, dimethyl sulfone, collagen protein; The disintegration of tablet performance that this method makes is good, and stripping is fast, and onset is rapid, and the consumption of raw material and various adjuvants reaches optimal proportion, and the stability of product strengthens, and has the high characteristics of absorption rate.
The specific embodiment
The effect of chondroitin sulfate comprises: 1, the effect of skeletonization.The formation of animal bone is on the fiber that Organic substances such as collagen protein form, and inorganic salts such as deposition calcium, phosphorus form.Chondroitin sulfate plays a part positive in the deposition process of calcium.Calcium in the bone often is that stripping limit, limit is sedimentary: promptly the calcium one side is dissolved out from bone; Calcium in absorbing blood and deposition and form new bone are in a kind of homeostasis process bone all the time.If chondroitin sulfate rope deficiency, the deposition of the calcium in the blood on bone will be subjected to certain influence.If can absorb calcium and chondroitin sulfate together, can make sclerotin solid and suppress the generation of osteopathia effectively to a certain extent; 2, the effect of protection cartilage.Be positioned at the joint of the connecting portion of bone and bone, promptly the top of bone is made up of cartilage, and cartilage then mainly is to be made of II collagen type and a large amount of proteoglycans.Filled up by joint fluid in the gap in joint, when pressurizeing for the joint repeatedly or when moving back and forth, joint fluid plays a part lubricated joint and protection joint, undertaking what joint fluid was sucked cartilage is exactly chondroitin sulfate.It is generally acknowledged that cartilage is in case destruction just is difficult to regeneration.
Have organic sulfur in the dimethyl sulfone, some basic functions of organic sulfur comprise the formation of keeping the human body internal protein, and the anti-inflammatory property of sulfur comprises that to some diseases arthritis, muscle and arthralgia etc. produce effect very much.The arthritic is studied, discovery patient cartilage sulfur content has only 1/3 of normal person's cartilage sulfur content, to suffering from the hand rheumatic arthritis, patients such as knee joint degenerative arthritis, omarthritis, neck arthritis carry out obeying day 2250mg dimethyl sulfone and blank test.Through six weeks, the misery of taking the blank group of dimethyl sulfone patient suffering ratio patient alleviates 80%.
Collagen protein is the main constituent of articular cartilage, and equally with age, the collagen protein synthesis ability also decreases, and cartilage elasticity reduces, fragility increases, the wearing and tearing aggravation, and various joint disease have just taken place thereupon.The collagen protein network structure is the framework of articular cartilage, and proteoglycan (D-glucosamine) waits other compositions to exist wherein as implant, increases the intensity of articular cartilage, and collagen protein runs off and aggravates.Network structure relaxes even ruptures, and makes proteoglycan ingredients from lossing such as (oxygen sugar) quicken.The articular cartilage degeneration takes place thereupon, causes the friction between bone and the bone, causes arthralgia.This shows that collagen protein is the key of articular cartilage health.Have only the human body of allowing to obtain sufficient collagen protein and proteoglycan (D-glucosamine), could more effectively quicken the joint rehabilitation.Therefore, the basic method of control joint slight illness is to want effective replenishing collagen.
The selection of disintegrating agent: disintegrating agent and kind and consumption are most important to disintegrate, the result of extraction of tablet, are the factors that at first will consider.The general disintegrating agent swellbility that requires to select for use is greater than 5ml/g, and the most frequently used have carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose, a crospolyvinylpyrrolidone etc.On the consumption, should at first consider of the influence of the kind of disintegrating agent to the disintegration of tablet behavior, even but same disintegrating agent, the difference on the consumption also may produce diametrically opposite effect to the disintegrate behavior of tablet.As a kind of fast disintegrant efficiently, have good water absorption and dilatancy as carboxymethyl starch sodium, the back volume that fully expands can increase 200-300 doubly.When its consumption of control is in 7%, can bring into play best disintegration, and in water, do not form stickiness solution and hinder tablet continuation disintegrate, carboxymethyl starch sodium is bondd in water and form hydration shell and be higher than 8% consumption in the sheet sub-surface, stop the infiltration of moisture on the contrary, slowed down the disintegrate of tablet.Test shows, in the different pharmaceutical preparation process, need to grope according to other adjuvant composition situation, for new medication preparation become tablet do not have can foundation ready-made composition proposal.
The selection of binding agent: some drugs itself or adjuvant mix afterwards inadhesion or stickiness is less, can adopt the aqueous solution of hydrophilic polymeies such as polyvinylpyrrolidone and hydroxypropyl emthylcellulose is binding agent, wherein commonly used with polyvinylpyrrolidone, seldom adopt starch slurry.It is bigger to adopt polyvinylpyrrolidone to do the particle surface hydrophilic that binding agent makes, and moisture easily infiltrates label and makes its quick disintegrate stripping behind the tabletting.Should consider the suitable composition and the ratio of binding agent during preparation, be beneficial to the disintegrate of tablet.
The selection of other adjuvant: generally disintegrate in water of tablet, suitable excipient can produce synergism to disintegrating agent, the normal good excipient of swellability that adopts as microcrystalline Cellulose, pregelatinized Starch and processing agar, can also be selected some lubricants such as magnesium stearate etc.
Below by embodiment the present invention is done further to specify, but be not limited only to following example.
Embodiment 1:
Glucosamine 700g
Microcrystalline Cellulose 121g
Carboxymethyl starch sodium 45g
Polyvinylpyrrolidone 35g
Tartaric acid 0.28g
Magnesium stearate 12g
Water is an amount of
Methanol is an amount of
Titanium dioxide 32g
Prepare according to following step:
1) part polyethylene ketopyrrolidine and tartaric acid are mixed, being configured to concentration with the mixed solvent of an amount of methanol and water is 10% binder solution, fully is dissolved to clear;
2) glucosamine is pulverized, crossed 120 mesh sieves;
3) stirred mixing 5 minutes in the polyvinylpyrrolidone dry powder input wet granulator with glucosamine and remainder;
4) add an amount of methanol and stirred 3 minutes, left standstill 10 minutes;
5) evenly, slowly add the solution of the binding agent of step 1 configuration, liquid feeding is granulated while stirring, behind the corning, and strict control inlet temperature, drying is crossed 20 mesh sieves;
6) in step 5 gained granule, add microcrystalline Cellulose, carboxymethyl starch sodium, magnesium stearate and fully mix, measure tabletting behind the intermediate content;
7) preparing titanium dioxide solution, compound concentration are 15%, and inlet temperature, sheet bed tempertaure, the leaving air temp of control during coating carries out coating to the tablet of step 6 gained.
Embodiment 2:
Glucosamine 700g
Chondroitin sulfate 350g
Collagen protein 150g
Microcrystalline Cellulose 121g
Carboxymethyl starch sodium 45g
Polyvinylpyrrolidone 35g
Tartaric acid 0.28g
Magnesium stearate 12g
Water is an amount of
Methanol is an amount of
Polyethylene Glycol 32g
Prepare according to following step:
1) part polyethylene ketopyrrolidine and tartaric acid are mixed, being configured to concentration with the mixed solvent of an amount of methanol and water is 10% binder solution, fully is dissolved to clear;
2) glucosamine is pulverized, crossed 120 mesh sieves;
3) stirred mixing 5 minutes in the polyvinylpyrrolidone dry powder input wet granulator with glucosamine and remainder;
4) add an amount of methanol and stirred 3 minutes, left standstill 10 minutes;
5) evenly, slowly add the solution of the binding agent of step 1 configuration, liquid feeding is granulated while stirring, behind the corning, and strict control inlet temperature, drying is crossed 20 mesh sieves;
6) in step 5 gained granule, add chondroitin sulfate, collagen protein, microcrystalline Cellulose, carboxymethyl starch sodium, magnesium stearate and fully mix, measure tabletting behind the intermediate content;
7) preparation polyglycol solution, compound concentration is 15%, inlet temperature, sheet bed tempertaure, the leaving air temp of control during coating carries out coating to the tablet of step 6 gained.
Claims (5)
1. compound combined formulation that is used to prevent and treat osteoarthrosis pain, comprise active component and adjuvant, it is characterized in that described active component is one or more the combination in glucosamine or glucosamine and other active component chondroitin sulfate, dimethyl sulfone, the collagen protein, glucosamine is glucosamine sulphate or hydrochlorate or phosphate or its mixture; Adjuvant comprises excipient, disintegrating agent, lubricant, binding agent, stabilizing agent, wetting agent, described excipient is a starch, microcrystalline Cellulose, sucrose, lactose, dextrin, mannitol, the combination of one or more in the calcium phosphate, disintegrating agent is a crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium, the combination of one or more in the cross-linking sodium carboxymethyl cellulose, lubricant is a magnesium stearate, stearic acid, the combination of one or both in the micropowder silica gel, binding agent is a polyvinylpyrrolidone, sodium carboxymethyl cellulose, starch, the combination of one or more in the hydroxypropyl emthylcellulose, stabilizing agent is a tartaric acid, and wetting agent is water or methanol or ethanol.
2. a kind of compound combined formulation that is used to prevent and treat osteoarthrosis pain according to claim 1 is characterized in that the weight proportion of described each component is as follows:
200～800 parts of glucosamine
200～500 parts of chondroitin sulfate
100～400 parts of collagen protein
100～300 parts of dimethyl sulfones
1～200 part of excipient
1～40 part of binding agent
1～100 part of disintegrating agent
1～50 part of lubricant
0.1～1 part of stabilizing agent
Wetting agent is an amount of.
3. a kind of compound combined formulation that is used to prevent and treat osteoarthrosis pain according to claim 1, it is characterized in that adjuvant also comprises the coating pre-mixing agent, the component of described coating pre-mixing agent solution is one or more the mixing in titanium dioxide, polyoxyethylene, Pulvis Talci, Polyethylene Glycol, hydroxypropyl emthylcellulose, the lecithin.
4. a kind of compound combined formulation that is used to prevent and treat osteoarthrosis pain according to claim 3 is characterized in that the weight proportion of described each component is as follows:
200～800 parts of glucosamine
200～500 parts of chondroitin sulfate
100～400 parts of collagen protein
100～300 parts of dimethyl sulfones
1～200 part of excipient
1～40 part of binding agent
1～100 part of disintegrating agent
1～50 part of lubricant
0.1～1 part of stabilizing agent
1～100 part of coating pre-mixing agent
Wetting agent is an amount of.
5. a kind of preparation method that is used to prevent and treat the compound combined formulation of osteoarthrosis pain according to claim 3 is characterized in that carrying out according to the following steps:
1) part binding agent and stabilizing agent are mixed, being configured to concentration with the mixed solvent of an amount of methanol and water is 1～25% binder solution, fully is dissolved to clear;
2) glucosamine is pulverized, crossed 60～120 mesh sieves;
3) stirred mixing 1～10 minute in the binding agent dry powder input wet granulator with glucosamine and remainder;
4) add an amount of methanol and stirred 1～3 minute, left standstill 1～10 minute;
5) evenly, slowly add the solution of the binding agent of step 1 configuration, liquid feeding is granulated while stirring, behind the corning, and strict control inlet temperature, drying is crossed 12～20 mesh sieves;
6) other active component of adding and excipient, disintegrating agent, lubricant fully mix in step 5 gained granule, tabletting behind the mensuration intermediate content;
7) preparation coating pre-mixing agent solution, compound concentration is 1～18%, inlet temperature, sheet bed tempertaure, leaving air temp during the control coating carry out coating to the tablet of step 6 gained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010184471 CN101822684B (en) | 2010-05-27 | 2010-05-27 | Compound combined preparation for preventing osteoarticular pain and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010184471 CN101822684B (en) | 2010-05-27 | 2010-05-27 | Compound combined preparation for preventing osteoarticular pain and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101822684A true CN101822684A (en) | 2010-09-08 |
| CN101822684B CN101822684B (en) | 2012-08-15 |
Family
ID=42686988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010184471 Active CN101822684B (en) | 2010-05-27 | 2010-05-27 | Compound combined preparation for preventing osteoarticular pain and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101822684B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102551045A (en) * | 2011-12-15 | 2012-07-11 | 广东汤臣倍健生物科技股份有限公司 | Collagen calcium tablet |
| CN102600458A (en) * | 2011-11-01 | 2012-07-25 | 江苏江山制药有限公司 | Compound preparation of glucosamine chondroitin and production method of compound preparation |
| CN103622978A (en) * | 2013-12-17 | 2014-03-12 | 吉林省名霖药业有限公司 | Stable glucosamine pharmaceutical composition and preparation method thereof |
| US9066926B2 (en) | 2013-10-24 | 2015-06-30 | Interhealth Nutraceuticals, Inc. | Method of reducing exercise-induced joint pain in non-arthritic mammals |
| CN114224860A (en) * | 2021-11-06 | 2022-03-25 | 山东润德生物科技有限公司 | Glucosamine calcium tablet preparation and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101648008A (en) * | 2009-09-04 | 2010-02-17 | 江苏江山制药有限公司 | Compound preparation used for joint care and preparation method thereof |
-
2010
- 2010-05-27 CN CN 201010184471 patent/CN101822684B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101648008A (en) * | 2009-09-04 | 2010-02-17 | 江苏江山制药有限公司 | Compound preparation used for joint care and preparation method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600458A (en) * | 2011-11-01 | 2012-07-25 | 江苏江山制药有限公司 | Compound preparation of glucosamine chondroitin and production method of compound preparation |
| CN102551045A (en) * | 2011-12-15 | 2012-07-11 | 广东汤臣倍健生物科技股份有限公司 | Collagen calcium tablet |
| US9066926B2 (en) | 2013-10-24 | 2015-06-30 | Interhealth Nutraceuticals, Inc. | Method of reducing exercise-induced joint pain in non-arthritic mammals |
| CN103622978A (en) * | 2013-12-17 | 2014-03-12 | 吉林省名霖药业有限公司 | Stable glucosamine pharmaceutical composition and preparation method thereof |
| CN114224860A (en) * | 2021-11-06 | 2022-03-25 | 山东润德生物科技有限公司 | Glucosamine calcium tablet preparation and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101822684B (en) | 2012-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101829125B (en) | Compound combined formulation for preventing and treating osteoarthrosis and preparation method thereof | |
| CN101648008B (en) | Compound preparation used for joint care and preparation method thereof | |
| US6767899B1 (en) | Composition and method for treatment of conditions having an inflammatory component | |
| JP5465824B2 (en) | Pharmaceutical preparation and method for producing the same | |
| CN101653451B (en) | Health product for keeping joint health and increasing bone density and preparation method thereof | |
| CN101822684B (en) | Compound combined preparation for preventing osteoarticular pain and preparation method thereof | |
| CN101888834A (en) | Oral dispersable tablet | |
| CN102526058A (en) | Anti-inflammatory analgesic medicinal composition containing lornoxicam and esomeprazole | |
| PL200957B1 (en) | Celecoxib compositions and the use thereof | |
| EA023807B1 (en) | Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic | |
| PL195603B1 (en) | Instant release oral formulation, application of low molecular peptide thrombin inhibitor, method for the production of the oral formulation as well as application of the mixture of microcrystalline cellulose and sodium starch glycolate | |
| CN104621432A (en) | Glucosamine composite tablets and preparation method thereof | |
| KR20090089867A (en) | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity | |
| CN101647805B (en) | Glucosamine chewable tablet used for relieving and preventing osteoarthritis and preparation method thereof | |
| KR20080047437A (en) | Composition comprising a nsaid and paracetamol | |
| CN102600458A (en) | Compound preparation of glucosamine chondroitin and production method of compound preparation | |
| CN1947724A (en) | Compound amino-glucose hydrochloride, chondroitin sulfate effervescent, tablets prepn. method and use thereof | |
| CN110507620A (en) | A kind of compound glucosamine sulfate dispersible tablet and preparation method thereof | |
| JP2007119453A (en) | Method for preventing lowering of bromhexine hydrochloride content | |
| CN102727456B (en) | Drug port cavity disintegrating tablet and preparation method thereof | |
| CN109453169B (en) | Application of bulleyaconitine A | |
| CN101642442B (en) | Tablets for preventing and curing osteoarthritis and preparation method thereof | |
| CN101982174A (en) | Formula of compound medicine preparation for relieving cough and preventing asthma and preparation method thereof | |
| CN1364464A (en) | Aminoglucose hydrochloride medicinal composition | |
| CN101125147A (en) | Glucosamine calcium medicine preparation, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100908 Assignee: Jiangsu Aland Nourishment Co.,Ltd. Assignor: Jiangshan Pharmaceutical Co., Ltd., Jiangsu Prov. Contract record no.: 2013320000489 Denomination of invention: Compound combined formulation for preventing and treating osteoarthrosis and preparation method thereof Granted publication date: 20120815 License type: Exclusive License Record date: 20130604 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU ALAND NOURISHMENT CO., LTD. Free format text: FORMER OWNER: JIANGSHAN PHARMACEUTICAL CO., LTD., JIANGSU PROV. Effective date: 20140121 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140121 Address after: 214500, Jiangshan Road, Jiangsu, Jingjiang 20 Patentee after: Jiangsu Aland Nourishment Co.,Ltd. Address before: 214500, Jiangshan Road, Jiangsu, Jingjiang 20 Patentee before: Jiangshan Pharmaceutical Co., Ltd., Jiangsu Prov. |